By Fineline Cube Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG: 1801), has entered into a partnership with compatriot firm Longbio Pharma. The RMB 500 million (USD 70 million) deal will leverage Altruist’s NDA filing experience, world-class quality system, and continuous stable commercial manufacturing capacities to support the market filing and commercial manufacturing of Longbio Pharma’s two drugs in China.
Leveraging Altruist’s Expertise in Biologics Manufacturing
Altruist, which specializes in the development and commercial manufacturing of antibodies, fusion proteins, ADCs, gene and cell therapies, and other drugs, boasts a manufacturing capacity of 140,000 liters in operation. This partnership will enable Longbio Pharma to benefit from Altruist’s extensive experience and capabilities, enhancing the market filing and commercial manufacturing processes for their drugs in China.
Longbio Pharma’s Background and Potential Impact
Longbio Pharma, co-founded by Dr. Sun Naichao, who played a significant role in the discovery of omalizumab and established US firm Tanox Inc., a NASDAQ-listed company later acquired by Genentech, brings a wealth of expertise to this collaboration. This partnership with Altruist Biotechnology is expected to accelerate the development and commercialization of Longbio Pharma’s drug candidates, further solidifying its position in the Chinese pharmaceutical market.-Fineline Info & Tech